Stempoint Capital’s Belite Bio BLTE Stock Holding History

Stempoint Capital’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,163	Closed	-$1.47M	–	90
2025 Q4	$1.47M	Buy	+9,163	New	+$1.09M	0.25%	63

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stempoint Capital's BLTE Position: Q1 2026 in Review

Stempoint Capital sold out of Belite Bio (BLTE) in Q1 2026, closing a stake of 9,163 shares — an estimated $1.47M sold.

Stempoint Capital first reported a position in BLTE in Q4 2025 and held it in 1 quarter. The position peaked at $1.47M in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

Stempoint Capital reported no remaining Belite Bio position as of Q1 2026 after selling out during the quarter.
Stempoint Capital sold 9,163 Belite Bio shares in Q1 2026, an estimated $1.47M.
Stempoint Capital first reported a position in Belite Bio in Q4 2025 and held it in 1 quarter.
Stempoint Capital's Belite Bio position peaked at $1.47M in Q4 2025.
75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.